A
Ann M. Lawler
Researcher at Johns Hopkins University School of Medicine
Publications - 32
Citations - 9731
Ann M. Lawler is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Gene & Transgene. The author has an hindex of 22, co-authored 32 publications receiving 9137 citations. Previous affiliations of Ann M. Lawler include Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Perinatal Loss of Ts65Dn Down Syndrome Mice
TL;DR: The results provide the first statistical and numerical evidence supporting the prenatal and perinatal pattern of loss in the Ts65Dn mouse model of DS.
Journal ArticleDOI
Human X inactivation center induces random X chromosome inactivation in male transgenic mice.
Barbara R. Migeon,Ethan Kazi,Camille Haisley-Royster,Jie Hu,Roger H. Reeves,Linda M. Call,Ann M. Lawler,Clara S. Moore,Harris Morrison,Peter Jeppesen +9 more
TL;DR: The results show for the first time that the DNA included in the human XIC transgene is sufficient to initiate random X inactivation, even in cells of another species.
Journal ArticleDOI
Craniofacial abnormalities resulting from targeted disruption of the murine Sim2 gene.
TL;DR: Its premature accumulation in Sim2 ‐/‐ animal palates suggests a regulatory role for Sim2 in HA synthesis and in the establishment of craniofacial architecture.
Journal ArticleDOI
Growth retardation and neonatal lethality in mice with a homozygous deletion in the C-terminal domain of RNA polymerase II.
Ying Litingtung,Ann M. Lawler,S. M. Sebald,E. Lee,John D. Gearhart,H. Westphal,Jeffry L. Corden +6 more
TL;DR: It is shown that mice homozygous for a deletion of thirteen of the 52 heptapeptide repeats are smaller than wild-type littermates and have a high rate of neonatal lethality, suggesting that the CTD plays a role in regulating growth during mammalian development.
Journal ArticleDOI
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans.
Norihisa Sakamoto,Kazuhide Tsuji,Kazuhide Tsuji,Linda M. Muul,Ann M. Lawler,Emanuel F. Petricoin,Fabio Candotti,Julia A. Metcalf,Jorge A. Tavel,H. Clifford Lane,Walter J. Urba,Bernard A. Fox,Ajit Varki,Joan K. Lunney,Amy S. Rosenberg +14 more
TL;DR: It is shown that in the majority of patients administered 3 different types of cell-based therapies using cells grown in fetal calf serum-containing media, an antibody response to bovine apolipoprotein B-100 develops after the second infusion and is the dominant specificity.